Lidocaine (hydrochloride hydrate)

• UNSPSC Description:

  Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia[1][2].

• Target Antigen:

  Apoptosis; ERK; MEK; NF-κB; Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;MAPK/ERK Pathway;Membrane Transporter/Ion Channel;NF-κB;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/lidocaine-hydrochloride-hydrate.html

• Purity:

  99.90

• Solubility:

  H2O : ≥ 100 mg/mL

• Smiles:

  O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.Cl.O

• Molecular Weight:

  288.81

• References & Citations:

  [1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  6108-05-0